Skip to main content
logo
Anavex Life Sciences Corp. (AVXL)
NASDAQ: AVXL · Real-Time Price · USD
2.990
-0.140 (-4.47%)
Aug 28, 2026, 4:00 PM EDT - Market closed

Anavex Life Sciences Cash Flow Statement

Millions USD. Fiscal year is Oct - Sep.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Sep '25 Sep '24 Sep '23 Sep '22 Sep '21
Net Income
-13.02-46.38-43-47.51-47.98-37.91
Stock-Based Compensation
-11.9411.559.4416.3718.388.23
Other Operating Activities
---0.85--
Change in Accounts Payable
-3.08-5.385.310.5-0.910.75
Change in Unearned Revenue
--0.04-0.080.47-0.44
Change in Other Net Operating Assets
-1.241.2-2.481.546.28-1.9
Operating Cash Flow
-29.29-39.04-30.81-27.79-24.24-30.38
Operating Cash Flow Growth
------

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Sep '25 Sep '24 Sep '23 Sep '22 Sep '21
Issuance of Common Stock
46.912.1411.9829.6522158.79
Repurchase of Common Stock
-0.45-2.71----
Other Financing Activities
-----0.71-5.55
Financing Cash Flow
46.459.4311.9829.6521.29153.24

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Sep '25 Sep '24 Sep '23 Sep '22 Sep '21
Net Cash Flow
17.16-29.61-18.841.87-2.95122.86

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Sep '25 Sep '24 Sep '23 Sep '22 Sep '21
Levered Free Cash Flow
-27.06-24.39-19.43-14.28-6.03-15.9
Unlevered Free Cash Flow
-27.06-24.39-19.43-14.28-6.03-15.9

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Sep '25 Sep '24 Sep '23 Sep '22 Sep '21
Cash Income Tax Paid
0.130.130.30.140.330.14
Change in Working Capital
-4.33-4.222.752.515.36-0.71
SEC Filings: 10-K · 10-Q